Thorough QT and QTc studies

Richmond Pharmacology has globally recognised expertise in cardiac safety, intensive ECG studies, cardiology overreading, statistical analysis, reporting and publishing.

Benefits of using Richmond Pharmacology

Short start-up times of 4-6 weeks, rapid data readout

Exceptional ECG generation facilitating ECG over reading

Established relationships with regulatory agencies in EU, USA and Japan.

Experts in cardiac safety with state-of-the-art equipment

Low data variability allowing for smaller sample sizes

Thorough and intensive QTc Studies

Our experience in conducting QTc studies spans two decades and we are proud of our track record of 100% success. This demonstrated in our published studies.

We provide consultancy and expert reports in cardiac safety, the clinical conduct of intensive ECG studies, core laboratory services such as adjudication and the cardiology over reading of automated interval measurements. Our clinical staff specialise in statistical analysis concentration effect modelling, reporting, and publishing.

We provide sponsors with FDA compliant state of the art analysis methods, and the option to include a non-pharmacological method of proving assay sensitivity. Our unique and innovative approach means that we conduct our studies and prove assay sensitivity as a standard feature. This has provided quality data in many Japanese bridging, SAD and MAD studies eliminating the need for a dedicated TQT study.

Unmatched expertise

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

Our core lab is situated at our clinical unit at London Bridge, offering a focused work environment with no additional costs, thereby delivering value for money to pharmaceutical sponsors.

We are a leading publisher in this area and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

adaptive img

Richmond Pharmacology develops optimal and cost-effective strategies for TQT waivers

qtc image

All QTc studies are performed in collaboration with world renowned opinion leaders in cardiological analysis

ema image

Richmond Pharmacology study data is well respected by regulators such as FDA, EMA and PMDA

Our experts

Professor Camm - Professor of Cardiology

Professor Camm's major speciality is cardiac arrhythmias but he is also much involved in clinical cardiac electrophysiology, cardiac pacemakers and risk stratification in post myocardial infarction, heart failure and cardiomyopathy drugs.

Read biography

Dr Jorg Taubel - MD FFPM
(CEO)

Dr Jorg Taubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in clinical pharmacology for over 24 years and during that time he has conducted more than 400 early phase studies..

Read biography

Experience

  • Track record of 100% success in conducting QTC studies
  • Many of our QTc studies have been published.

Set-up

  • State of the art methods and equipment
  • Tried and tested processing for ECG adjudication and data analysis

We are

  • Excellence in ECG acquisition allows meaningful ECG analysis
  • Option to include a non-pharmacological method of proving assay sensitivity

RPL's ECG Core Lab

Richmond Pharmacology's Core ECG Laboratory was established in 2004 to provide centralized digital and manual ECG data analysis for Richmond Pharmacology's in house TQT trials, in addition to ECG reading, analysis and reporting for clinical trials.

Read more

Why Choose RPL for TQT Studies

Richmond Pharmacology provides their clients with FDA compliant manual over-read QT interval measurement and analysis by a team of highly trained and experienced cardiologists.

Our Cardio Analysis Services

Richmond Pharmacology's Core ECG Laboratory has worked with numerous clinical units worldwide and participated in 200 clinical trials sponsored by pharmaceutical companies.

Read more

Digital ECG Analysis and Cardiologist Experience

Thorough QT/QTc (TQT) studies are today an integral component in the development of new chemical entities (NCE) and on going drug development programmes.

Read more

Latest news

Upcoming Event

The Future of Healthcare.

13:00 – 17:00, 8th December 2021
Join Richmond Pharmacology, The Royal Free Hospital and Richmond Research Institute as we share breakthroughs in cardiac health from gene editing to RNA interference therapies.
View event

The future of clinical workforce training programmes, an exclusive interview with MedCity

November 30, 2021
Ulrike Lorch discusses the future of clinical workforce training programmes in an exclusive interview with MedCity
Read more

Richmond Pharmacology’s Dr Emma Akuffo joins fellow EUCROF task force members as a finalist at TOPRA Awards 2021

November 17, 2021
EUCROF task force members compete for a prize at the TOPRA Awards 2021
Read more

Developing talent in the fast-changing clinical research environment

November 2, 2021
In a feature article for PharmaTimes, Dr. Ulrike Lorch, Medical Director at Richmond Pharmacology, outlines how investing in the clinical research workforce is crucial to delivering high quality, cutting-edge trials and achieving faster drug development
Read more